Karyopharm Therapeutics
Kim N. has extensive experience in finance and accounts payable, currently serving as the Accounts Payable Manager at Karyopharm Therapeutics Inc. since January 2020. Prior to this role, Kim N. held the same position at Alnylam Pharmaceuticals from May 2017 to January 2020, and was the Accounts Payable Leader at Biogen from November 2011 to May 2017. Kim N. began a finance career at MassBiologics, working as an Accounts Payable/Payroll Administrator from February 2005 to February 2012. Kim N. pursued education at Curry College, Northeastern University, and Regis College, focusing on Human Resources Management and Services at former St. Thomas Aquinas at Newton.
Karyopharm Therapeutics
13 followers
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).